Smoking Among UK Students at Historic Low: NHS Digital

Sep.07.2022
Smoking Among UK Students at Historic Low: NHS Digital
Smoking among school students in England has hit a record low at 3%, according to NHS Digital. However, over 20% of 15-year-old girls now use e-cigarettes, which is reminiscent of smoking levels over a decade ago. The statistics also show progress in reducing underage drinking and drug use.

Newly released statistics from NHS Digital have revealed that the proportion of smoking students has hit a record low of 3%. However, alarmingly, over 20% of 15-year-old girls are now using e-cigarettes, bringing to mind the smoking levels seen over a decade ago. This data suggests a worrying trend towards a new form of nicotine addiction among young people. Photo credit: David Jones/PA.


A study has revealed that in 2021, 21% of 15-year-old girls admit to currently using electronic cigarettes, more than twice the amount recorded by NHS Digital in 2018 (10%). The percentage of girls using e-cigarettes is 7 percentage points higher than their male peers of the same age.


The 2021 report on smoking, drinking, and drug use among young people in England shows a decrease in the percentage of students who self-report as smokers from 5% in 2018 to 3% in 2021, reaching an all-time low. As of 2021, less than one-eighth of secondary school students (12%) have ever smoked, which is the lowest number since comparable records began in 1982.


The number of people using electronic cigarettes has reached a historical high. In 2021, 9% of students have tried e-cigarettes, which is the highest number on record, compared to 6% in 2018. Girls aged 15 are most likely to do so, with over one-fifth of people reporting current use and 12% saying they use e-cigarettes frequently. The last time regular smoking rates were this high among 15-year-old girls was in 2010, when 14% reported being regular smokers.


However, the study also revealed progress in reducing alcohol and drug use. According to new data released by NHS Digital, only 18% of 11 to 15-year-old teenagers in England reported having used drugs by 2021, down from 24% in 2018. Last year, only 40% of students reported having drunk alcohol, down from 44% in both 2018 and 2016.


According to data, high school students with stronger social skills- those who frequently interact with people outside of their family or school- are more likely to have tried illegal drugs, alcohol, or smoking compared to those who rarely meet others. Among those who interact with people outside of their family or school on a daily basis, nearly one-fifth (19%) have used drugs in the past month. In contrast, 8% of those who socialize outside of their home or school a few times a week and 5% of those who only meet with people outside of their home or school once a week have used drugs in the past month. Among those who have not met anyone in the past month, only 2% have used drugs.


According to statistical data, Covid-19 may have played a role in the decrease in drug usage, as the early 2021 restrictions may have limited young people's opportunities to socialize outside of school. The proportion of students who have tried nitrous oxide (known as laughing gas) has decreased significantly. In 2021, only 3% of students had tried it, a decrease of 2.8 percentage points since 2018. The proportion of high school students who have tried glue and solvents has decreased by 2.2 percentage points to 6.8%, while cocaine usage has decreased from 1.8% to 1.4%.


Reducing drug use, alcohol consumption and smoking may have a positive impact on the mental health and well-being of young people. Last month, more than half of children who used drugs reported low levels of happiness during that time, while only 26% of children who did not smoke, drink or use drugs reported feeling happy.


Statement


This article is compiled from third-party information and is intended for industry discussion and learning purposes.


This article does not necessarily reflect the viewpoint of 2FIRSTS and we cannot confirm the authenticity and accuracy of its content. The translation of this article is solely for the purpose of industry exchange and research.


Due to limitations in our translation abilities, the translated version of this article may not accurately reflect the original text. Please refer to the original article for accuracy.


2FIRSTS aligns completely with the Chinese government on any domestic, Hong Kong, Macao, Taiwan, and foreign issues and positions.


The copyright of compiled information belongs to the original media and author. If there is any infringement, please contact us for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Special Report|Virginia Vape Directory Shows Contrast Between Vuse and JUUL Pod Systems and CrossBar 20K, Loon Flavored Disposables
Special Report|Virginia Vape Directory Shows Contrast Between Vuse and JUUL Pod Systems and CrossBar 20K, Loon Flavored Disposables
A 2Firsts analysis of Virginia's liquid nicotine and vapor product certification directory identified 213 product records from 15 manufacturers. Companies associated with BAT, Altria, Imperial Brands, JTI and JUUL account for 127 entries. The directory also includes independent brands CrossBar 20K, Loon and Breeze. CrossBar advertises a 13mL disposable capable of up to 20,000 puffs, while Loon has 16 disposable entries featuring fruit, cooling and beverage-related flavors. Of all records, 120 are labeled as under FDA PMTA review. Virginia introduced revised penalties on October 1, 2026, including a minimum first-violation civil penalty of $5,000 per unlisted product, alongside new retail tobacco permitting requirements.
Regulations
Oct.30
JTI Proposes 25-Cent Irish Cigarette Tax Increase, Says It Could Raise €45 Million
JTI Proposes 25-Cent Irish Cigarette Tax Increase, Says It Could Raise €45 Million
Japan Tobacco International's Irish business has proposed a €0.25 tax increase on a pack of 20 cigarettes in its pre-Budget 2027 submission, below the €0.50-or-more increases typically imposed in recent Irish budgets. JTI says the proposal could generate around €45 million in additional Exchequer revenue while limiting further movement toward illicit and non-Irish-tax-paid tobacco. Revenue's existing estimate for a comparable €0.25 increase, including pro-rata rises on other tobacco products, is about €18 million for a full year.
JTI
Sep.18 by 2Firsts Perspectives
PMI Launches Fourth IQOS Convenience-Store Discount of 2026 for Black Friday in Japan, Cutting ILUMA i ONE to About $19 After Ploom AURA Fell to About $9
PMI Launches Fourth IQOS Convenience-Store Discount of 2026 for Black Friday in Japan, Cutting ILUMA i ONE to About $19 After Ploom AURA Fell to About $9
Philip Morris Japan launched its fourth confirmed nationwide convenience-store discount campaign for IQOS ILUMA i devices in 2026 on October 26, cutting three models by as much as ¥2,000, or about $12.70. The campaign began one day after JT ended a promotion that reduced Ploom AURA to ¥1,480, or about $9.40. JT says Ploom's share of Japan's heated-products category rose from 10.9% in January 2024 to 18.3% in June 2026, a gain of 7.4 percentage points, while PMI says IQOS still held about 68% category share in the third quarter. At the same time, Japan's two-stage heated-tobacco tax adjustment has pushed stick prices higher, leaving device discounts as an increasingly important tool for lowering the upfront cost of customer acquisition.
Market
Oct.28
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
A U.S. Government Accountability Office audit found that 131,915 tobacco product applications submitted to the FDA since 2018 remained without a final review as of December 31, 2025, with pending applications waiting an average of 1,266 days. GAO also found FDA lacks the data needed to systematically determine whether scientific reviews meet applicable timelines. HHS agreed to upgrade the agency's tracking systems. At the same time, FDA has begun applying lessons from its nicotine pouch PMTA pilot to e-cigarette reviews, while changes to enforcement policy and electronic submissions are making the specific stage of a PMTA increasingly relevant to market access.
FDA
Oct.03
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
At the 2026 NACS Show in Las Vegas, Philip Morris International (PMI) showcased its ZYN nicotine pouches, IQOS heated tobacco products and U.S. investments. A 2Firsts review of FDA records found that several ZYN products displayed at the booth were not on the agency's marketing authorization list, including certain nicotine strengths and flavors. A PMI booth representative also confirmed that IQOS is currently sold in three U.S. states, while the newer IQOS ILUMA system remains under FDA review.
EXPO
Oct.10
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane’s 2026 update of its living review on electronic cigarettes for smoking cessation included 80 randomized controlled trials involving 29,861 adult smokers, with nine trials added in this update. The review retained its high-certainty conclusion that nicotine e-cigarettes increase smoking cessation rates compared with nicotine replacement therapy. In absolute terms, about 10 in 100 people using nicotine e-cigarettes may quit smoking for at least six months, compared with about 6 in 100 using NRT. The review found no clear difference in serious adverse event rates between the two groups, while longer-term safety and the relative effectiveness of newer device types remain less certain.
Sep.07